TELA BIO, INC. (TELA): Price and Financial Metrics


TELA BIO, INC. (TELA): $11.78

-0.25 (-2.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TELA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TELA POWR Grades

  • TELA scores best on the Sentiment dimension, with a Sentiment rank ahead of 62.13% of US stocks.
  • The strongest trend for TELA is in Growth, which has been heading up over the past 177 days.
  • TELA ranks lowest in Quality; there it ranks in the 5th percentile.

TELA Stock Summary

  • TELA BIO INC's stock had its IPO on November 8, 2019, making it an older stock than just 15.95% of US equities in our set.
  • With a price/sales ratio of 6.04, TELA BIO INC has a higher such ratio than 80.79% of stocks in our set.
  • As for revenue growth, note that TELA's revenue has grown 42.66% over the past 12 months; that beats the revenue growth of 79.98% of US companies in our set.
  • Stocks that are quantitatively similar to TELA, based on their financial statements, market capitalization, and price volatility, are PWFL, XERS, MYO, BLBX, and INGN.
  • Visit TELA's SEC page to see the company's official filings. To visit the company's web site, go to www.telabio.com.

TELA Valuation Summary

  • TELA's EV/EBIT ratio is -5.5; this is 155.56% lower than that of the median Healthcare stock.
  • TELA's price/earnings ratio has moved down 0.6 over the prior 39 months.

Below are key valuation metrics over time for TELA.

Stock Date P/S P/B P/E EV/EBIT
TELA 2023-01-20 6.0 9.9 -5.4 -5.5
TELA 2023-01-19 5.7 9.4 -5.1 -5.2
TELA 2023-01-18 5.9 9.7 -5.3 -5.4
TELA 2023-01-17 6.0 9.9 -5.4 -5.5
TELA 2023-01-13 5.7 9.3 -5.1 -5.2
TELA 2023-01-12 5.6 9.2 -5.0 -5.1

TELA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TELA has a Quality Grade of C, ranking ahead of 27.58% of graded US stocks.
  • TELA's asset turnover comes in at 0.295 -- ranking 132nd of 183 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows TELA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.295 0.635 -0.825
2021-03-31 0.230 0.614 -0.754
2020-12-31 0.217 0.617 -0.700
2020-09-30 0.220 0.605 -0.624
2020-06-30 0.260 0.613 -0.546
2019-12-31 0.325 0.600 -0.536

TELA Price Target

For more insight on analysts targets of TELA, see our TELA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

TELA Stock Price Chart Interactive Chart >

Price chart for TELA

TELA Price/Volume Stats

Current price $11.78 52-week high $13.37
Prev. close $12.03 52-week low $5.15
Day low $11.74 Volume 21,100
Day high $12.18 Avg. volume 25,167
50-day MA $10.29 Dividend yield N/A
200-day MA $8.71 Market Cap 225.69M

TELA BIO, INC. (TELA) Company Bio


TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.


TELA Latest News Stream


Event/Time News Detail
Loading, please wait...

TELA Latest Social Stream


Loading social stream, please wait...

View Full TELA Social Stream

Latest TELA News From Around the Web

Below are the latest news stories about TELA BIO INC that investors may wish to consider to help them evaluate TELA as an investment opportunity.

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 4,200 shares of its comm

Yahoo | January 20, 2023

TELA Bio Announces U.S. Commercial Launch of NIVIS™ Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds

Company grows product portfolio, expanding product offerings to optimize soft tissue preservation and restorationMALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced the commercial launch of its NIVIS Fibrillar Collagen Pack. NIVIS Fibrillar Collagen Pack

Yahoo | January 9, 2023

TELA Bio: Can Rally Extend Into FY23? (NASDAQ:TELA)

TELA recently broke out from an 18-week long sideways channel. Click here to see whether it can sustain and extend this rally into 2023.

Seeking Alpha | December 24, 2022

One TELA Bio, Inc. (NASDAQ:TELA) insider upped their stake by 342% in the previous year

Looking at TELA Bio, Inc.'s ( NASDAQ:TELA ) insider transactions over the last year, we can see that insiders were net...

Yahoo | December 23, 2022

TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference

MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the 41 st Annual J.P. Morgan Healthcare Conference on January 12 th , 2023.

GlobeNewswire | December 21, 2022

Read More 'TELA' Stories Here

TELA Price Returns

1-mo 6.32%
3-mo 29.03%
6-mo 47.25%
1-year 2.26%
3-year -22.24%
5-year N/A
YTD 2.43%
2022 -10.16%
2021 -14.89%
2020 16.14%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7541 seconds.